PeptiDream Inc. (TYO:4587)
Japan
· Delayed Price · Currency is JPY | Market Cap | 230.13B |
| Revenue (ttm) | 46.68B |
| Net Income (ttm) | 14.82B |
| Shares Out | 129.61M |
| EPS (ttm) | 114.21 |
| PE Ratio | 15.55 |
| Forward PE | 14.80 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 953,600 |
| Average Volume | 642,510 |
| Open | 1,800.00 |
| Previous Close | 1,775.50 |
| Day's Range | 1,743.00 - 1,800.00 |
| 52-Week Range | 1,665.00 - 3,060.00 |
| Beta | 0.24 |
| RSI | 39.91 |
| Earnings Date | May 13, 2025 |
About PeptiDream
PeptiDream Inc., a biopharmaceutical company, engages in the discovery and development of constrained peptides, small molecules, and peptide-drug conjugate therapeutics. The company develops its products based on its Peptide Discovery Platform System, a drug finding platform that enables the production of non-standard peptide libraries for the identification of potent and selective macrocyclic peptide candidates, which then can be developed into peptide-based, small molecule-based, peptide-drug conjugate, and multi-functional peptide conjugates... [Read more]
Financial Performance
In 2024, PeptiDream's revenue was 46.68 billion, an increase of 62.57% compared to the previous year's 28.71 billion. Earnings were 15.01 billion, an increase of 394.70%.
Financial StatementsNews
PeptiDream: Opulent Dream Now A Reality
PeptiDream's PDPS platform offers a promising investment opportunity due to the new therapeutic class of macrocyclic peptide. Read my analysis of PPTDF stock.